Genentech's Ocrevus (ocrelizumab) is now available to UK patients with relapsing remitting MS (RRMS) after the National Institute for Health and Care Excellence (NICE) recommended the drug on Friday (June 22). About 100,000 people in the UK live with MS, and 85% have a relapsing-remitting form eligible for treatment with ocrelizumab. Ocrelizumab has been shown to reduce the number of relapses per year by nearly half and to slow the risk of progression of the disease compared with current treatment. Jo Sopala, Director of Development at the MS Trust welcomed the decision to make the drug routinely available, commenting, “We welcome this positive NICE review for RRMS, and hope that it brings us closer to the treatment being made available to people with early [primary progressive] PPMS too.” Roche/Genentech reports that it is working with NICE to ensure people with early PPMS are also able to access ocrelizumab through the NHS. Click here for Pharm Exec's Brands of the Year report on Ocrevus.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.